NeurAxis expands payer coverage with four new medical policies for IB-Stim pediatric neurostimulation
Summary
NeurAxis announced four new medical policies from major payers covering the IB-Stim auricular neurostimulation device for pediatric cyclic vomiting syndrome and irritable bowel syndrome in early 2026. The expanded coverage represents a significant commercial milestone for the company, bringing the total number of covered lives significantly higher and enabling broader adoption beyond the academic and tertiary centers where the device was initially used.
Why it matters
Four new payer policies simultaneously is a rare commercial win for a pediatric medical device company — it suggests payer HTA committees reviewed real-world outcomes data and found the cost-effectiveness case compelling. IB-Stim's success demonstrates that peripheral nerve stimulation for gastrointestinal conditions is a commercially viable bioelectronic medicine application beyond the established cardiovascular and neurological indications.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial